Bristol-Myers, Samsung BioLogics expand drug manufacturing agreement
Both the companies’ have not disclosed the financial terms of the agreement. In July 2013, both the firms have entered into their first manufacturing agreement to collaborate in
Ionis Pharmaceuticals has entered a licence agreement granting global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.
The early administration of plasma has an important role in reducing battlefield mortality rates, and therefore the USAMMDA has prioritized the development of a freeze-dried plasma product. Currently,